Fig. 2: p85β plays an oncogenic role in cancer cells with PIK3CA helical domain mutations.
From: Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer
a High levels of PIK3R2 (p85ß) are associated with worse survival of patients whose tumors harbor a PIK3CA helical domain mutation. COAD, BLCA, UCEC, and BRAC datasets were downloaded from TGCA and combined. Patients were divided into three groups according to their PIK3CA mutation status: Helical domain mutations, Non-helical domain mutations, and wild-type. Kaplan-Meier analyses of 5-year survival of patients whose tumors expressing high levels of PIK3R2 vs low levels of PIK3R2 were performed. HR: Hazard Ratio. b–i Knockout of p85β impairs the growth of cancer cells with a PIK3CA E545K mutation, but not cells with WT PIK3CA or a PIK3CA H1047R mutation. PIK3R2 was knocked out in the indicated cell lines, and the cells were assayed for: Western blot analyses of p85β, p110α, and p110β proteins (b, f); cell proliferation (c, g); colony formation (d, h); and xenograft tumor (10 tumors/group) growth (e, i). Statistical analyses, two-way ANOVA was used for c, e, f and h, and student’s t-test (two-tailed) was used for d, i. Data are presented as mean ± SEM of three independent experiments. Source data are provided as a Source Data file.
